Scarica l'app Stockscreener
15.70
2.61%
-0.42
Dopo l'orario di chiusura:
15.55
-0.15
-0.96%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché KROS Giù?
Forum
Previsione
Precedente Chiudi:
$16.12
Aprire:
$16.14
Volume 24 ore:
447.65K
Relative Volume:
1.08
Capitalizzazione di mercato:
$637.66M
Reddito:
-
Utile/perdita netta:
$-168.05M
Rapporto P/E:
-3.0604
EPS:
-5.13
Flusso di cassa netto:
$-146.15M
1 W Prestazione:
-1.51%
1M Prestazione:
+0.32%
6M Prestazione:
+28.27%
1 anno Prestazione:
-72.83%
Intervallo 1D:
$15.68
$16.18
Intervallo di 1 settimana:
$15.50
$16.57
Portata 52W:
$9.12
$72.37
Keros Therapeutics Inc Stock (KROS) Company Profile
Nome
Keros Therapeutics Inc
Settore
Industria
Telefono
617-314-6297
Indirizzo
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Confronta KROS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
15.70 | 654.72M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-01-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-12-16 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-12-16 | Reiterato | Oppenheimer | Outperform |
| 2024-12-13 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-12 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-12-12 | Downgrade | TD Cowen | Buy → Hold |
| 2024-12-12 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | Iniziato | Jefferies | Buy |
| 2024-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-09-23 | Iniziato | Guggenheim | Buy |
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-02-21 | Iniziato | William Blair | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-07-31 | Iniziato | Wedbush | Outperform |
| 2023-07-26 | Iniziato | BofA Securities | Buy |
| 2023-02-14 | Iniziato | Cowen | Outperform |
| 2022-10-18 | Iniziato | Truist | Buy |
| 2022-07-26 | Iniziato | BTIG Research | Buy |
| 2020-12-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-04 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-04 | Iniziato | Jefferies | Buy |
| 2020-05-04 | Iniziato | Piper Sandler | Overweight |
| 2020-05-04 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Keros Therapeutics Inc Borsa (KROS) Ultime notizie
Can volume confirm reversal in Keros Therapeutics Inc.2025 Price Action Summary & Intraday High Probability Setup Alerts - newser.com
What analysts say about Keros Therapeutics Inc stockPrice Support Zones & High Yield Trading Signals - earlytimes.in
Keros Therapeutics Inc. stock daily chart insightsMarket Volume Summary & Long Hold Capital Preservation Tips - newser.com
Published on: 2025-10-10 05:54:47 - newser.com
Weiss Ratings Reaffirms "Sell (D)" Rating for Keros Therapeutics (NASDAQ:KROS) - MarketBeat
Investors in Keros Therapeutics (NASDAQ:KROS) have unfortunately lost 72% over the last year - Yahoo Finance
Can machine learning forecast Keros Therapeutics Inc. recoveryPortfolio Value Summary & Expert Verified Movement Alerts - newser.com
Public Employees Retirement System of Ohio Purchases Shares of 26,103 Keros Therapeutics, Inc. $KROS - MarketBeat
Can Keros Therapeutics Inc. recover in the next quarterMarket Performance Recap & Growth Oriented Trading Recommendations - newser.com
Can Keros Therapeutics Inc. rally from current levelsGap Down & Weekly Market Pulse Alerts - newser.com
Will Keros Therapeutics Inc. bounce back from current supportQuarterly Earnings Report & Long-Term Capital Growth Strategies - newser.com
How to interpret RSI for Keros Therapeutics Inc. stockWeekly Stock Summary & Proven Capital Preservation Methods - newser.com
Quantitative breakdown of Keros Therapeutics Inc. recent moveTake Profit & Risk Controlled Stock Pick Alerts - newser.com
Is Keros Therapeutics Inc. stock poised for growthTrade Analysis Report & Growth Oriented Trade Recommendations - newser.com
What momentum indicators show for Keros Therapeutics Inc. stockWeekly Risk Report & Verified Entry Point Signals - newser.com
Keros Therapeutics Inc Stock Analysis and ForecastHigh Yield Income Stocks & Low Entry Cost Investment - earlytimes.in
Is Peeti Securities Limited Positioned to Benefit From Geographic ExpansionSector Performance Review & Achieve Triple Digit Returns - earlytimes.in
Is Keros Therapeutics Inc a good long term investmentEconomic Indicators Overview & Affordable Market Investment - earlytimes.in
What drives Keros Therapeutics Inc stock priceContrarian Investment Ideas & Today’s Picks, Tomorrow’s Winners - earlytimes.in
Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting - ADVFN
Keros Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
Assenagon Asset Management S.A. Purchases 36,360 Shares of Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics: A Potential Dart Throw (NASDAQ:KROS) - Seeking Alpha
TGF-β Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Is now a turning point for Keros Therapeutics Inc.Watch List & Reliable Price Breakout Alerts - newser.com
CEO Change: Whats next for National Storage Affiliates Trust stockMarket Trend Report & Weekly High Potential Stock Alerts - خودرو بانک
Layoff Watch: Is Liberty Global Ltd stock risky to hold now2025 Investor Takeaways & Entry and Exit Point Strategies - خودرو بانک
Acadian Asset Management LLC Invests $1.50 Million in Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics Inc Azioni (KROS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Keros Therapeutics Inc Azioni (KROS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 10% Owner |
Apr 09 '25 |
Buy |
10.13 |
934,258 |
9,464,512 |
4,392,737 |
| Seehra Jasbir | CHIEF EXECUTIVE OFFICER |
Apr 04 '25 |
Option Exercise |
0.30 |
49,367 |
14,810 |
302,223 |
5.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):